Search

Displaying results 2131 - 2140 of 8967 in total
  1. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection. … Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV)

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Indication

    Epiphora

    go.drugbank.com/conditions/DBCOND0034135
    Drugs: Chlorpheniramine · Choline salicylate · Loratadine · Pholcodine
    Synonyms: Epiphora, unspecified as to cause
  3. Indication

    Vision Disorders

    go.drugbank.com/conditions/DBCOND0035879
    Drugs: Almitrine · Faricimab · Ranibizumab
    Synonyms: Reduced ability to see
  4. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    for continued cancer growth. … Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy.

    Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20
  5. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis … , and as a lubricant for artificial eyes.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in the absence of MAPK signaling.

    Mixtures: Avmapki Fakzynja Co-pack
  8. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

  9. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and

  10. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market